Waters Corporation (WAT) 2025 Earnings Quality Report

Grade: F — Major Red Flags

Framework: Schilit *Financial Shenanigans* + Beneish M-Score + forensic accounting principles

Data: SEC EDGAR 10-K (Filed 2026-02-23) + Yahoo Finance

Auditor: PricewaterhouseCoopers LLP — Clean opinion, auditor since 1994

One-line verdict: Waters Corporation had a solid 2025 — net sales of $3.17B up 7% (its first real growth year since 2022) with China rebounding +10%, chemistry consumables +12%, and operating cash flow of $653M generating free cash flow of $540M. Then on February 9, 2026 — six weeks after year-end — Waters closed the Reverse Morris Trust acquisition of BD's Biosciences & Diagnostic Solutions (BDS) business and assumed $4.0 billion of unsecured term loans from SpinCo, with the $3.5B Tranche A maturing in 364 days and "expected to be refinanced with long-term bond financing." The 2025 10-K captures a company at the pivot point: three red flags on the screen (AR outpaced revenue for two consecutive years, cash $0.6B covers only 39% of $1.5B debt BEFORE the BDS deal, and goodwill/intangibles already at 74% of equity pre-acquisition), plus a Critical Audit Matter from PwC on product revenue recognition timing that takes on new significance given the 2025 AR growth. After the February 2026 closing, Waters's debt stack nearly quadruples to ~$5.5B — the 2025 10-K is the last clean pre-deal snapshot.

Two Segments Plus a Third Coming in February 2026

Per the MD&A: "The Company has two operating segments: Waters and TA. Waters products and services primarily consist of high-performance liquid chromatography (HPLC), ultra-performance liquid chromatography (UPLC and, together with HPLC, referred to as LC), mass spectrometry (MS), light scattering and field-flow fractionation instruments (Wyatt), and precision chemistry consumable products and related services. TA products and services primarily consist of thermal analysis, rheometry and calorimetry instrument systems and service sales."

On February 9, 2026: "The Company completed the acquisition of the BD Biosciences & Diagnostic Solutions Businesses (BDS). The transaction was structured as a Reverse Morris Trust transaction, where the BDS Business was spun off to BD shareholders and simultaneously merged with a wholly-owned subsidiary of the Company. The 2025 financial results of the BDS Business are not included in the Company's 2025 consolidated financial results presented herein."

The 2025 10-K is a clean pre-BDS snapshot. The March 31, 2026 10-Q will be a very different company.

Results of Operations: Clean 7% Growth Year

Per the Financial Overview table in MD&A (dollars in thousands):

Net sales grew 7% — the first real growth year since the Wyatt acquisition bump in 2023. But operating income DECLINED $23M despite the top-line growth because SG&A surged 20%. Per the MD&A: "Operating income of $803 million in 2025, decreased $23 million from the operating income of $826 million in 2024 primarily due to the impact of the higher sales volume, which was offset by the change in sales mix, the impact of merit increases on the Company's annual payroll in 2025 and approximately $82 million of transaction, integration and other internal costs associated with the BDS Business Acquisition. In addition, operating income for 2025 included the impact of $20 million of expenses associated with the Company's new ERP system implementation."

So of the $140M SG&A increase, $102M is BDS + ERP one-time costs. Underlying SG&A growth is closer to 5-6%.

Gross margin held: Cost of sales at 40.7% of revenue (vs. 40.6% in 2024). Operating margin fell 2.5 points due to the one-time costs. EPS was essentially flat at $10.76 because net income was rescued by a $22M drop in net interest expense (refinancing helped) and a modest tax benefit.

Geographic: China Back on Its Feet

Per the MD&A:

China rebounded from -10% in 2024 to +10% in 2025. Europe also grew 10% (with a 6% FX tailwind). Instrument system sales grew 5% (vs. -6% in 2024), and recurring revenue (chemistry + service) grew 8% — the high-margin razor-blade piece of the business. Chemistry alone grew 12%, which the MD&A attributes to "the uptake in columns and application-specific testing kits to pharmaceutical customers."

Cash Flow: $109M Decline on 7% Revenue Growth

Per the MD&A:

The MD&A explains the $109M CFFO decline: "The decrease in cash flows from operating activities in 2025 was driven by $24 million in additional tax payments associated with the final 2018 Tax Reform Transition payment, $52 million of costs related to the implementation of the Company's new ERP system and $29 million of payments made in connection with transaction and integration costs associated with the BDS Business Acquisition."

That is $105M of one-time cash outflows against a $109M decline — essentially all of it explained. Adjusted for these items, underlying operating cash generation was comparable to 2024. CFFO/NI at 1.02 is near unity, suggesting clean earnings quality.

Still, the screening engine flagged A2 (AR vs Revenue Growth) as "AR outpaced revenue for 2 consecutive years." That is worth noting. Accounts receivable grew faster than revenue in both 2024 and 2025. The 2025 CFFO data does not scream deterioration, but the AR trajectory warrants watching — particularly given PwC's selection of Product Revenue Recognition as its Critical Audit Matter.

PwC's Critical Audit Matter: Product Revenue Recognition

From the auditor's report: "Product Revenue Recognition... The Company recognizes revenue on product sales at the time control of the product transfers to the customer. Certain of the Company's customers have terms where control of the product transfers to the customer on shipment, while others have terms where control transfers to the customer on delivery. Product sales totaled $2.0 billion for the year ended December 31, 2025. The principal consideration for our determination that performing procedures relating to product revenue recognition is a critical audit matter is a high degree of auditor effort in performing procedures related to the Company's product revenue recognition."

PwC — Waters's auditor since 1994 — chose product revenue recognition timing as the single most judgmental area of the 2025 audit. That is notable in the context of the A2 red flag (AR outpaced revenue for two consecutive years). Revenue recognized at shipment (before delivery) can create a timing gap where revenue appears in Q4 but cash comes in Q1 — mechanically raising DSO and AR. The CAM does not say anything is wrong. But it does say PwC devoted high auditor effort to the line item where the screening engine saw the divergence.

Balance Sheet BEFORE the BDS Deal

Cash of $0.6B covers only 39% of $1.5B debt — a C4 red flag. Goodwill and intangibles of $1.9B represent 74% of equity — a D1 red flag. Both are acquisition-driven (Wyatt in 2023, Halo Labs in 2025, BDS pending in Q1 2026).

Per the MD&A: "In connection with the BDS Business Acquisition, on January 8, 2026, SpinCo entered into a Term Loan Credit Agreement with the lenders... On February 6, 2026 (the Funding Date), SpinCo borrowed $4.0 billion of unsecured term loans under the SpinCo Credit Agreement, consisting of a $3.5 billion tranche which will mature and be payable in full 364 days after the Funding Date (Tranche A) and a $500 million tranche which will mature and be payable in full on the second anniversary of the Funding Date (Tranche B)... Upon consummation of the BDS Business Acquisition, all of this indebtedness was assumed by Waters. Tranche A is expected to be refinanced with long-term bond financing, while Tranche B is expected to be repaid prior to maturity."

Post-closing, Waters's debt stack becomes $1.5B + $4.0B = $5.5B, against the same ~$0.6B of cash. The 2026 10-K will look significantly different.

The existing credit facility was also amended May 22, 2025: "pursuant to which the Company, among other things, reduced the aggregate total borrowing capacity of its existing senior unsecured revolving credit facility (the Credit Facility) by up to $200 million for an aggregate principal amount of up to $1.8 billion. The Credit Facility will mature on May 22, 2030."

The Tariff Wildcard

From the MD&A: "In August 2025, the U.S. Court of Appeals for the Federal Circuit ruled against certain of the U.S. tariffs that have been implemented. On February 20, 2026, the U.S. Supreme Court rendered a decision invalidating tariffs imposed under the International Emergency Economic Powers Act. This decision introduces uncertainty regarding potential refund processes and future trade policy actions and could affect the Company's cost structure and supply chain planning."

Waters manufactures in the U.S., Ireland, U.K., and Singapore. The February 20, 2026 Supreme Court decision is recent enough that the financial impact is not yet in the 10-K. Net net: for Waters the tariff invalidation is likely a positive — but refund processes are uncertain, and the underlying tariff regime may be reconstituted under a different legal basis.

The 18-Point Screening

Beneish M-Score at -2.37 is just inside the "non-manipulator" zone, closer to the threshold than TMO or UNH. Paired with PwC's revenue recognition CAM and the A2 red flag on AR outpacing revenue, this deserves continued monitoring in 2026.

Key Risks from the 10-K

1. BDS Acquisition Integration and Leverage

Per Item 1A Risk Factors: "The Company's failure to successfully integrate the BDS Business within the expected timeline could adversely affect the Company's future results... The amount of indebtedness that the Company assumed as a result of the BDS Business Acquisition is substantial and could adversely affect the Company's operational flexibility and increase its borrowing costs... The Company and SpinCo are required to abide by potentially significant restrictions that could limit the Company's ability to undertake certain corporate actions that otherwise could be advantageous."

Reverse Morris Trust transactions come with strict tax-driven restrictions to preserve the tax-free treatment — the acquirer typically cannot issue more than 50% equity or engage in certain transactions for at least 2 years after closing. Waters has committed to an all-debt acquisition with those restrictions.

2. Tariffs and Supply Chain Exposure

Per the MD&A: "The Company sells and services its customers in over 35 countries outside of the U.S. and we have manufacturing operations in the U.S., Ireland, U.K. and in Singapore where we utilize subcontractors with worldwide capabilities. In 2025, the U.S. government issued varying levels of tariffs on all imported goods into the U.S., including a baseline 10% tariff... These tariffs, any resulting retaliatory tariffs and any related supply-chain disruptions could have a significant impact on the Company's consolidated statement of operations and statement of cash flows."

The February 20, 2026 Supreme Court decision adds uncertainty, not clarity.

3. Customer Research Budget Cuts

Per Item 1A: "Reductions in customers research budgets or government funding may adversely affect the Company's business... Changes in government priorities as it relates to healthcare could affect the revenue earned by the Company and the costs for obtaining such revenue."

The 10-K also notes: "In addition to changes in trade policy, the new U.S. administration has implemented a number of other regulatory, policy and personnel changes, including the elimination, downsizing and reduced funding of certain government agencies and programs and the cancellation or delay of government contracts and research grants." Waters's academic and government customer base is sensitive to these changes.

4. AI Technology Risks

Per Item 1A: "Issues and uncertainties related to the development, deployment and use of AI in the Company's business operations and products may result in harm to the Company's reputation, regulatory action or legal liability."

5. Currency and International Operations

Europe is 30% of sales, Asia 33%. Foreign currency translation had minimal impact in 2025 after a -1% headwind in 2024. Any material USD strength would reverse.

6. Acquisition History

Per Item 1A: "The Company may face risks associated with previous or future acquisitions, strategic investments, joint ventures and divestitures." Wyatt ($1.3B in 2023) and now BDS have built a significant intangible asset base.

Key Financial Trends (3-Year)

Summary

Grade: F. Three red flags that are partly artifacts of a healthy year interrupted by a transformational acquisition.

Waters's underlying 2025 performance was strong:

But three red flags trip the framework:

Important context: The Beneish M-Score of -2.37 is just inside the non-manipulator zone but closer to the threshold than other healthcare companies we screened. The F-Score of 1.44 implies only 0.52% manipulation probability. The Altman Z of 10.03 reflects a company with minimal financial leverage (again, pre-BDS). PwC has audited Waters for 31 years without issue. None of this is a manipulation story.

What the 2026 10-K will tell us:

What would change our view: DSO stabilizing, BDS Tranche A refinanced with investment-grade bonds, integration costs tapering by year-end 2026, and a deleveraging timeline visible in the 2026 MD&A.

**Disclaimer**: This report is based on Waters Corporation's fiscal year 2025 10-K filed with the SEC on February 23, 2026. This is NOT investment advice.

**About EarningsGrade**: We screen earnings reports for financial red flags using an 18-point forensic framework. Grade F means major red flags were detected that warrant thorough investigation.